Physician profile
Amila Silva
NPI 1083855670
$23,683.97
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $245 · 2021: $13K · 2022: $6,948 · 2023: $2,130 · 2024: $862.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,800 · Food and Beverage: $191.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,800.00 |
| Food and Beverage | $191.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Research LLC | $19,341.85 | 2021-2024 | |
| Alcon Vision LLC | $2,931.39 | 2021 | |
| Genentech USA, INC. | $430.96 | 2019-2023 | Vabysmo |
| Regeneron Healthcare Solutions, INC. | $305.94 | 2021-2024 | Eylea Hd |
| Alimera Sciences, INC. | $227.81 | 2021-2024 | Yutiq, Iluvien |
| Allergan, INC. | $159.71 | 2021 | |
| Apellis Pharmaceuticals, INC. | $128.33 | 2022 | |
| Abbvie INC. | $66.00 | 2024 | |
| Novartis Pharmaceuticals Corporation | $23.91 | 2021 | |
| Genentech, INC. | $20.82 | 2019 | |
| Summit Surgical Corp. | $17.84 | 2021 | |
| Ocular Therapeutix, INC. | $15.57 | 2024 | Dextenza |
| Astellas Pharma US INC | $13.84 | 2024 | Izervay |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amila Silva listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.